Literature DB >> 2021626

A transforming growth factor beta (TGF-beta) receptor from human placenta exhibits a greater affinity for TGF-beta 2 than for TGF-beta 1.

E J Mitchell1, M D O'Connor-McCourt.   

Abstract

Affinity-labeling techniques have been used to identify three types of high-affinity receptors for transforming growth factor beta (TGF-beta) on the surface of many cells in culture. Here we demonstrate that membrane preparations from tissue sources may also be used as an alternative system for studying the binding properties of TGF-beta receptors. Using a chemical cross-linking technique with 125I-TGF-beta 1 and 125I-TGF-beta 2 and bis(sulfosuccinimidyl)suberate (BS3), we have identified and characterized two high-affinity binding components in membrane preparations derived from human term placenta. The larger species, which migrates as a diffuse band of molecular mass 250-350 kDa on sodium dodecyl sulfate-polyacrylamide electrophoresis gels, is characteristic of the TGF-beta receptor type III, a proteoglycan containing glycosaminoglycan (GAG) chains of chondroitin and heparan sulfate. The smaller species of molecular mass 140 kDa was identified as the core glycoprotein of this type III receptor by using the techniques of enzymatic deglycosylation and peptide mapping. Competition experiments, using 125I-TGF-beta 1 or 125I-TGF-beta 2 and varying amounts of competing unlabeled TGF-beta 1 or TGF-beta 2, revealed that both the placental type III proteoglycan and its core glycoprotein belong to a novel class of type III receptors that exhibit a greater affinity for TGF-beta 2 than for TGF-beta 1. This preferential binding of TGF-beta 2 to placental type III receptors suggests differential roles for TGF-beta 2 and TGF-beta 1 in placental function.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2021626     DOI: 10.1021/bi00231a034

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Identification of a structural domain that distinguishes the actions of the type 1 and 2 isoforms of transforming growth factor beta on endothelial cells.

Authors:  S W Qian; J K Burmester; J R Merwin; J A Madri; M B Sporn; A B Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

2.  Mapping of the ligand binding domain of the transforming growth factor beta receptor type III by deletion mutagenesis.

Authors:  M C Pepin; M Beauchemin; J Plamondon; M D O'Connor-McCourt
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

3.  Characterization of transforming growth factor-beta (TGF-beta) receptors on BeWo choriocarcinoma cells including the identification of a novel 38-kDa TGF-beta binding glycoprotein.

Authors:  E J Mitchell; K Lee; M D O'Connor-McCourt
Journal:  Mol Biol Cell       Date:  1992-11       Impact factor: 4.138

4.  Characterization of distinct functional domains of transforming growth factor beta.

Authors:  J K Burmester; S W Qian; A B Roberts; A Huang; S Amatayakul-Chantler; L Suardet; N Odartchenko; J A Madri; M B Sporn
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

Review 5.  TGF-beta3 and cancer: a review.

Authors:  H G Laverty; L M Wakefield; N L Occleston; S O'Kane; M W J Ferguson
Journal:  Cytokine Growth Factor Rev       Date:  2009-08-04       Impact factor: 7.638

6.  Changes in maternal serum transforming growth factor beta-1 during pregnancy: a cross-sectional study.

Authors:  Mandeep Singh; Ngozi C Orazulike; Jill Ashmore; Justin C Konje
Journal:  Biomed Res Int       Date:  2013-11-18       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.